Primary Cardiac Lymphoma: Lessons Learned from a Long Survivor

Area of Science:

• Oncology
• Cardiology
• Hematology

Background:

• Primary cardiac lymphoma (PCL) is an exceptionally rare malignancy affecting the heart or pericardium.
• Patients diagnosed with PCL typically face a poor prognosis, with a median survival of approximately 7 months.

Purpose of the Study:

• To report a unique case of a long-term survivor with PCL.
• To discuss the potential benefits of early intervention with automated implantable cardioverter-defibrillators (AICDs) in managing arrhythmias associated with PCL.
• To highlight the possibility of late and unusual relapse patterns in PCL.

Main Methods:

• Case report of a 63-year-old woman diagnosed with PCL.
• Treatment with chemoimmunotherapy.
• Prophylactic implantation of an AICD.
• Follow-up detailing disease progression and relapse.

Main Results:

• The patient achieved remission with chemoimmunotherapy and survived for over 7 years.
• She experienced a late relapse of PCL, presenting as breast recurrence, and subsequently died from small cell lung cancer.
• The prophylactic AICD was in place, though the ultimate cause of death was unrelated to cardiac arrhythmia.

Conclusions:

• Chemoimmunotherapy demonstrates efficacy in achieving remission for PCL.
• Prophylactic AICD implantation may mitigate early mortality from life-threatening arrhythmias in PCL patients.
• Late and atypical relapse patterns warrant further investigation in PCL management.
• This case represents one of the longest survival durations reported for PCL.